

Extensive Assessment of Cytokine Production Following Immune Cell Stimulation on the NovoCyte Penteon using the LEGENDplex Bead-based Multiplex Assay

Author

Lauren Jachimowicz and
Garret Guenther
Agilent Technologies, Inc.

In collaboration with:



Abstract

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or therapeutics. Measuring cytokine production and the source of cytokine production is important for an in-depth understanding of the immune response in primary samples, such as from pathogenic infections, or novel therapeutics to ensure unintended cytokine responses do not occur. The BioLegend LEGENDplex COVID-19 Cytokine Storm Panel 1 and 2 run on the Agilent Penteon flow cytometer was used to quantify the secretion of 27 cytokines, providing an in-depth snapshot of the cytokine response. Intracellular cytokine staining using flow cytometry provided additional information to determine the frequency of cytokine-producing cells and identify the cell populations producing cytokines. Using both bead-based cytokine production quantification and intracellular cytokine assays provides a deeper understanding of the cytokine response by immune cells.

Introduction

Cytokines are small proteins acting as soluble messengers, which are responsible for communication between nearby cells. Signaling by cytokines can modulate gene regulation, innate and adaptive immune response, and inflammation. Cytokine storm syndrome is a life-threatening inflammatory response involving rapid, uninhibited overproduction of cytokines and related molecules leading to hyperactivation of the immune system. Cytokine storm syndrome can be triggered by various therapies, cancers, and pathogens including COVID-19, resulting in systemic inflammation, acute respiratory distress (ARDS), and multi-organ damage. COVID-19 induced cytokine storm holds a central role in the severity of the disease, suggesting that the virus-induced inflammatory response is what determines the most severe COVID-19 symptoms. Investigations have shown increases of several cytokines in severe COVID-19 patients including IL-1 β , IL-1RA, IL6, IL-7, IL8, IL9, IL10, basic FGF, GCSF, GMCSF, IFN γ , CXCL10, MCP1, MIP1A, MIP1B, PDGF, TNF α , and VEGF. In turn, IL-1 β and IL-6 are being investigated for potential therapeutic targets for the treatment of COVID-19. Outside of COVID-19, cytokine production has been shown to determine the severity of many other pathogenic infections, and the identification, as well as quantification, of cytokines produced in biological samples can elucidate the complexity of a viral-induced immune response.

Cytokine production can be measured directly by quantifying the amount of cytokine protein using analyte-specific antibodies. The most common and least expensive method used for cytokine measurement is the enzyme-linked immunosorbent assay (ELISA). In this process, an analyte-specific antibody is used to immobilize the cytokine to a solid surface and is then complexed with an

antibody linked to an enzyme providing a readout. The readout can be used to determine the concentration of the cytokine in the sample. However, each ELISA is limited to one analyte, restricting the total number of cytokines that can be measured simultaneously. Array-based cytokine measurements can measure many cytokines at the same time, but offer only qualitative information on the presence/absence of a cytokine and require specialized equipment to perform. On the other hand, bead-based, multiplex flow cytometry assays follow similar principles as an ELISA, but the reaction occurs on a bead instead of a plate. Using easily distinguished beads, this assay allows the simultaneous assessment of many cytokines, providing accurate quantification of cytokine concentrations with high detection sensitivity, and a broader dynamic range than traditional methods. All of these assays quantify the amount of secreted cytokine produced; however, it can be useful to determine which cells are responsible for secreting which cytokine. Intracellular cytokine staining can detect the specific cytokines produced in different cell types with the use of cell surface markers. Determining the concentration of secreted cytokine, as well as the cell type producing said cytokine, provides important information on the immune cell response to stimuli.

Due to the clinical results of CD28 superagonist monoclonal antibody (TGN 1412), which resulted in severe cytokine storm syndrome development, the cytokine release assay has become routine for screening novel therapeutics under investigation. It is primarily used to assess the risk of developing inflammatory responses to new agents. Individual labs may differ in their approach to the cytokine release assay, but all are measuring immune cell activation by stimulation that results in cytokine secretion. Positive controls are known cytokine

release syndrome stimulants, such as CD3-OKT3 antibody, lipopolysaccharide, TGN1412, or mitogens, such as PMA. Most of the cytokine release assays performed focus on three to 12 different cytokines, primarily released from T cells or NK cells, while most assays detect three of the four common cytokines, interferon- γ (IFN- γ), tumor necrosis factor- α (TNF α), interleukin-6 (IL-6) and interleukin-8 (IL-8). Some laboratories extend this panel by including IL-1 β , IL-2, IL-5, IL-10, IL-12, or IL-17. Having a targeted panel of just a few cytokines can be effective when you know which cell is most likely to be stimulated with the therapeutic being investigated; however, a positive cytokine response would potentially be missed in cells types other than T and NK cells, since most cytokines assessed are specifically produced by T or NK cells. Also, performing ELISA assays on many samples can be a time-consuming and labor-intensive process. An assay that can quantify the production of a large number of cytokines simultaneously, while providing a fast and easy workflow, will allow for the easier discovery of new and unpredicted cytokine responses in both pathogenic infections and responses to novel therapeutics.

In this application note, two immune stimulators, α CD3 antibody or LPS, were used to activate PBMC from two donors. Cytokine production was measured for 27 different cytokines using the BioLegend LEGENDplex COVID-19 Cytokine Storm Panel 1 and 2, which measure 14 cytokines and 13 cytokines, respectively. The LEGENDplex COVID-19 Cytokine Storm Panel detection kits contain different concentrations of APC fluorescent-encoded capture beads in two sizes. Capture beads are conjugated with an antibody specific for each cytokine and can be segregated into an analyte-specific population by the combination of size and APC fluorescence. When combined

with a sample containing the target cytokine, each analyte will bind to its specific capture bead and, using a similar principle to the sandwich-immunoassay, biotinylated detection antibody cocktail is added followed by streptavidin-phycoerythrin (SA-PE) so that the PE signal provides a fluorescent readout to determine the cytokine concentration. This assay allows for the simultaneous assessment of up to 14 cytokines in one well, saving sample and time. It also provides a higher detection sensitivity and broader dynamic range than traditional methods. For the examples we show here, flow cytometric intracellular cytokine staining was coupled with cell surface markers to determine the cell population responsible for key cytokines IL-2, IFN- γ , and TNF α . Intracellular cytokine staining can show which cell is responsible for producing specific cytokines and is essential in determining which cells to target when trying to mediate a cytokine storm response. Using the secreted cytokine production assessment with the LEGENDplex assays (in conjugation with intracellular staining) on Agilent NovoCyte flow cytometers means that more information can be obtained in a single experiment on the quantity and nature of cytokines produced.

Materials and methods

Reagents

- Ficoll-Paque PLUS (Millipore Sigma GE17-1440-02)
- Human IgG control antibody (R&D Systems 1-001-A)
- α CD3 antibody Clone OKT3 (50-112-2025)
- Lipopolysaccharide (Fisher 50-112-2025)
- BioLegend CytoFix/CytoPerm (BioLegend 426803)
- Brefeldin-A solution (BioLegend 317325)
- Flow cytometry antibodies and viability dye (vendor and catalog number listed in Table 1)
- RPMI 1640 medium with GlutaMAX (Gibco)
- LEGENDplex COVID-19 Cytokine Storm Panel 1 (14-plex) (Biolegend 741089)
- LEGENDplex COVID-19 Cytokine Storm Panel 2 (13-plex) (Biolegend 741112)

PBMC isolation and cell stimulation

PBMC were isolated according to the manufacturer's instructions and resuspended in RPMI 1640 GlutaMAX, supplemented with 10% FBS. Cells were plated (1 million cells/mL) with LPS (1 ng/mL) or added to α CD3 or IgG antibodies coated on 96-well microplates with and without the addition of Brefeldin-A. Antibodies were coated at 1 μ g/mL for 2 hours at 37 °C, the excess antibody was removed by washing wells with media before plating cells.

Flow cytometric analysis of intracellular cytokine production

After 15 hours of incubation with stimulation reagents and Brefeldin-A, cells were collected for flow cytometry staining. Cells were stained with Zombie UV viability dye in PBS at a dilution of 1:500 for 10 minutes at room temperature and were protected from light, followed by an antibody cocktail of CD45 PE-Dazzle 595, CD3 BV510, CD4 PercpCy5.5, CD8 BV785, CD19 FITC, CD14 BV711, CD56 BV605, and CD16 BUV737 that were added for

Table 1. Flow cytometry panel for peripheral mononuclear cell cytokine production analysis.

Antibody	Supplier	Part Number	Cell Type
Zombie Dye UV	Biolegend	423107	Viability
CD45 PE-Dazzle 595	Biolegend	368529	
CD3 BV510	Biolegend	344827	T cells
CD4 PercpCy5.5	Biolegend	317427	
CD8 BV785	Biolegend	344739	
CD56 BV605	Biolegend	362537	NK Cells
CD19 FITC	Biolegend	302205	B cells
CD14 BV711	Biolegend	367139	Monocytes
CD16 BUV737	BD	612786	
IL-2 APC	Biolegend	500309	Cytokine Production-Intracellular
TNF α BV421	Biolegend	502931	
IFN γ PE	Biolegend	506506	

20 minutes at room temperature, also protected from light. Next, cells were fixed using Cyto-Fast Fix/Perm kit for 20 minutes at room temperature and were protected from light. They then were washed with Cyto-Fast Perm wash solution and resuspended in IL-2 APC, TNF α BV421, IFN- γ PE antibodies, diluted in perm wash solution for 20 minutes at room temperature, and were protected from light. Cells were acquired on the NovoCyte Penton flow cytometer and analyzed using the NovoExpress software.

Quantification of cytokine production using the LEGENDplex bead-based flow cytometry assay

At 24 and 48 hours after stimulation, the supernatant was collected from wells to quantify the concentration of 27 cytokines using the LEGENDplex COVID-19 cytokine storm panel 1 and panel 2, following the manufacturer's instructions. Samples were analyzed using the NovoCyte Penton and data were analyzed using the LEGENDplex analysis software.

Results and discussion

Examination of intracellular cytokines is one of the few assays that allow for the identification of cytokine-producing cells without requiring isolation of a pure cell population first. A flow cytometry panel was designed for the NovoCyte Penton to determine the frequency of cells producing three major cytokines, IL-2, IFN γ , and TNF α , with surface markers to identify major cell populations in PBMC: Monocytes, T cells, NK cells, and B cells (Table 1). PBMC were stimulated either with plate-bound α CD3 antibody, LPS, IgG control, or PBS control for 15 hours. Brefeldin-A was added to cells to block the secretion of cytokines so cytokines can be detected within cells. After 15 hours of stimulation, cells were stained with a Zombie UV viability dye, CD45 PE-Dazzle 595, CD3 BV510,

CD4 PercpCy5.5, CD8 BV785, CD19 FITC, CD14 BV711, CD56 BV605, and CD16 BUV737 antibodies. Cells were then fixed and stained for intracellular cytokines using IL-2 APC, TNF α BV421, and IFN- γ PE antibodies. Cells were acquired on the NovoCyte Penton and analyzed using NovoExpress software. After gating single cells using forward scatter (FSC) height and area, live cells were identified as Zombie UV negative cells (Figure 1). Next, lymphocyte and monocyte populations were gated based on side scatter (SSC) and expression of CD45 and lymphocyte populations were further distinguished by expression of CD19 and CD3, identifying B lymphocytes T lymphocytes, respectively. The CD19-CD3- population was then analyzed for the expression of CD56 to identify NK cells, while the CD3+ T cells were categorized into either CD4+ or CD8+ T cells. Monocyte populations were identified by the expression of CD14 or CD16; however, CD16 and CD14 expression on monocytes decrease rapidly *in vitro*. It has been reported that following even short *in vitro* incubation of monocytes, CD16 expression is lost, explaining the low frequency of CD16+ cells in these experiments. Therefore, monocyte populations were identified for downstream analysis by SSC and CD45 expression alone, and monocytes, T cells, B cells, and NK cells were each analyzed for production of IL-2, TNF α , and IFN- γ .

α CD3 antibody activation specifically targets the T cell receptor (TCR) pathway, resulting in rapid T cell activation. Generally, when T cell activation and cytokine production are measured, T cells are cultured for 3 to 5 days and then restimulated with mitogens PMA/Ionomycin to cause rapid cytokine release. In this study, we aimed to determine if early-stage T cell activation was easily measured by intracellular staining to enable a quick assay for cytokine production and activation that does not rely on proxy cellular activation

markers. For this, IL-2, IFN- γ , TNF α producing CD3+ T cells were quantified 15 hours after stimulation and compared to IgG-stimulated controls in PBMC from two donors (Figure 2). CD3+ T cells were approximately 3% IL-2+, 4% IFN- γ +, and 7.5% TNF α +, and a significant portion of these cells were positive for more than one marker. In control IgG stimulated samples, no significant cytokine production was seen. IFN- γ and TNF α cytokine production occurred in the NK and monocyte populations from indirect activation by activated T cells (Figure 1, see NK and monocyte population). Therefore, analyzing early production of cytokines in α CD3 antibody-activated PBMC is achievable for T cells, NK cells, and monocytes.

LPS is a molecule naturally occurring in the cell wall of gram-negative bacteria that results in rapid immune activation and the release of inflammatory cytokines. During a bacterial infection, if the cytokine response is not correctly regulated, inflammatory cytokines are overproduced, resulting in tissue damage. LPS has been shown to activate monocyte populations through the cell surface Toll-like receptor 4 (TLR4). Many studies look at short-term (less than 6 hours) LPS stimulation resulting in rapid monocyte activation and cytokine production. Here, the effect of low concentration LPS stimulation for a longer incubation time was investigated to determine if different stimulations agents (such as α CD3 and LPS) could be analyzed in one experiment and to determine if any unanticipated cytokines appear after a longer incubation. After 15 hours with LPS (about a tenth of the typical concentration used), PBMC were stained with the same flow cytometry panel, as described in Figure 3. There was a substantial number of TNF α -producing monocytes in both donor PBMCs at 22 and 23%. No significant amount of IL-2 or IFN- γ was observed from monocytes, which was

expected, as T cells are the main drivers of IL-2 and IFN- γ production. Cytokine production from other cell populations was not observed after LPS stimulation. Together, this data verifies that PBMC is activated following α CD3 and LPS and that LPS is specifically activating the monocyte population. While α CD3 antibody targets T cells, it also results in indirect cytokine production from NK and monocyte populations.

To further investigate the cytokines produced from activated PBMC, the Biolegend LEGENDplex COVID-19 cytokine storm panel was used to measure the secretion of 27 cytokines. PBMC were stimulated as described, either with LPS or α CD3 antibody or controls. After 24- and 48-hour stimulation, cell culture supernatant was collected and used for cytokine

analysis. The LEGENDplex COVID-19 Cytokine Storm Panel 1 quantifies the expression of IL-6, CCL2 (MCP-1), G-CSF, IFN- α 2, CCL5 (RANTES), IL-2, IFN- γ , IL-7, IL-1RA, CXCL8 (IL-8), TNF α , CXCL10 (IP-10), CCL3 (MIP-1a), and IL-10. The LEGENDplex COVID-19 Cytokine Storm Panel Panel 2 quantifies the expression of IL-13, GM-CSF, IL-1 β , IL-5, sCD25 (IL-2Ra), IL-4, VEGF, IL-17A, IL-18, APRIL,




Figure 1. Gating strategy for cell specific cytokine production. Gating hierarchy used for the flow cytometry panel described in Table 1. Isolated peripheral blood mononuclear cells (PBMCs) were stimulated with LPS or added to an anti-CD3 antibody coated plate and cultured from 15 hours with the addition of Brefeldin A. The example shown in this figure was stimulated with CD3 antibody. Cells were then stained with antibody panel and analyzed on the NovoCyte Penton.




Figure 2. T Cytokine production after αCD3 antibody activation. PBMCs were activated 15 hours on αCD3 (right) or IgG (left) control coated microtiter plates (1 μg/mL) followed by antibody staining. CD3⁺ T cells were gated according to the gating hierarchy shown in Figure 1 and then assessed for production of IFN-γ (A), TNFα (B), and IL-2 (A,B).




Figure 3. Monocyte Cytokine production after αCD3 antibody activation. PBMCs were activated 15 hours with PBS control (A, left) or LPS 1 mg/mL (A, right) followed by antibody staining. Monocytes were gated according to the gating hierarchy shown in Figure 1, then assessed for production of TNFα, IL-2, and IFN-γ (IFN-γ not shown) (A). TNFα positive cells were then assessed for expression of monocyte markers CD14 and CD16 (B).

CCL4 (MIP-1b), IL-15, and IL-12p70. This covers many inflammatory and anti-inflammatory cytokines that are produced by several cell populations including T cells and monocytes. Cytokine production after α CD3 stimulation was compared to controls by the fold change, relative to IgG, and

cytokine production after LPS stimulation was compared using fold change relative to PBS (Figure 4). In Figure 4, the results from one donor at 48 hours were plotted for all 27 cytokines. Most cytokines increased (aside from APRIL and IL-15) under both stimulation conditions. Only small increases, less than a 10-fold

change, were seen in the secretion of IFN- α 2, IL-7, and VEGF. Notably, small differences were seen between the two donors in the quantity of cytokines produced; however, both displayed the same trend in the production of cytokines at 24 and 48 hours (data not shown).




Figure 4. Assessment of the secretion of 27 cytokines with the LEGENDplex COVID-19 Cytokine Storm Panels 1 and 2. Isolated PBMCs were stimulated with LPS (1 ng/mL) PBS control or α CD3/IgG control coated microtiter plates (1 μ g/mL). Supernatant was collected at 24- and 48-hour post stimulation. Cytokine production was quantified used the LEGENDplex COVID-19 Cytokine Storm Panels 1 and 2. Here, the fold change in secreted concentration was compared from α CD3 stimulation to IgG control (grey) and LPS to PBS control (green). Any samples that was over the limit of detection was set as the highest value on the standard curve so that fold change could still be calculated.

Next, the concentration of cytokines that increased more with either α CD3 or LPS stimulation were plotted to further investigate the results (Figure 5). α CD3 antibody stimulation of PBMCs increased IL-2, IFN- γ , IL-1RA, TNF α , CXCL10, IL-13, GM-CSF, IL-5, sCD25, IL-4, and IL-12p70 at least 10 times more than

LPS stimulation. Almost all the cytokines upregulated with α CD3 stimulation are produced by T cells, excluding CXCL10 and IL-12p70, which are primarily produced by monocytes and are induced by IFN γ (highly produced after CD3 stimulation). This demonstrates that the *in vitro* PBMC response to CD3 is driven by T cells, but also can be influenced by

other cells present. Cytokines that highly increased in the LPS sample include IL-6, CC2, G-CSF, IL-1b, IL-18, and CCL4, which are all primarily produced by monocytes and macrophages. This confirms that the *in vitro* PBMC response to LPS is primarily driven by monocyte and macrophage activation.




Figure 5. Assessment of the secretion of 27 cytokines with the LEGENDplex COVID-19 Cytokine Storm Panels 1 and 2. Isolated PBMC were stimulated with LPS (1 ng/mL) PBS control or α CD3/IgG control coated microtiter plates (1 μ g/mL). Supernatant was collected at 24- and 48-hour post stimulation. Cytokine production was quantified used the LEGENDplex COVID-19 Cytokine Storm Panels 1 and 2. Cytokines that were highly upregulated in the CD3 stimulated cells specifically are shown in (A) and those cytokines highly upregulated in LPS stimulated cells are shown in (B).

Conclusion

The flow cytometry-based LEGENDplex assays can be used to assess cytokine production and immune activation due to a novel biologic, therapeutic, or pathogen both for *in vitro* and biological samples. These cytokine panels that detect cytokines derived from monocytes, T cells, and NK cell activation provide an in-depth analysis of the immune cell response following stimulation. Using the LEGENDplex bead-based cytokine detection assay permits an unbiased assessment of cytokine production, which can elucidate unknown immune cell responses. Cytokine response assays used to assess cytokine responses to novel therapeutics primarily measure cytokines produced by T cells, which may result in an undetected cytokine response before further *in vivo* testing. When coupling cytokine measurements with intracellular cytokine staining, the cellular origin of the cytokine produced can also be used to provide more insight on cell types influenced by the stimulation. Using these two assays together allows for a detailed assessment of immune cell activation.

References

1. Fajgenbaum, D. C. *et al.* Cytokine Storm. *N. Engl. J. Med.* **2020**, 383, 2255–2273 DOI: 10.1056/NEJMra2026131
2. Finco, D. *et al.* Cytokine Release Assays: Current Practices and Future Directions. *Cytokine* **2014**, 66(2), 143–155
3. Zirui, M. *et al.* The Trinity of COVID-19: Immunity, Inflammation and Intervention. *Nature Reviews Immunology* **2020**, 20(6), 363–374. doi:10.1038/s41577-020-0311-8
4. de la Rica, R.; Borges, M.; Gonzalez-Freire, M. COVID-19: In the Eye of the Cytokine Storm. *Front. Immunol.* **2020** Sep 24, 11, 558898. doi: 10.3389/fimmu.2020.558898. PMID: 33072097; PMCID: PMC7541915.
5. Huang, C. *et al.* Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet* **2020**, 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5
6. Lucas, C. *et al.* Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19. *Nature* **2020**, 584, 463–469. <https://doi.org/10.1038/s41586-020-2588-y>
7. Lawlor, N. *et al.* Single Cell Analysis of Blood Mononuclear Cells Stimulated Through CD3 and CD28 Shows Collateral Activation of B and NK Cells and Demise of Monocytes. *bioRxiv* **2020**, 12.23.424147. <https://doi.org/10.1101/2020.12.23.424147>

www.agilent.com/chem

For Research Use Only. Not for use in diagnostic procedures.

RA44420.382037037

This information is subject to change without notice.

© Agilent Technologies, Inc. 2021
Printed in the USA, November 2, 2021
5994-4033EN